Petros Pharmaceuticals, Inc.
PTPI
$0.032
$0.00082.56%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | 299.12% | -5.87% | -28.71% | -44.85% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 299.12% | -5.87% | -28.71% | -44.85% |
| Cost of Revenue | -- | 67.49% | -29.74% | -35.96% | -- |
| Gross Profit | -- | 188.17% | 1.83% | -26.20% | -- |
| SG&A Expenses | -2.97% | -49.65% | 14.96% | 1.64% | -29.46% |
| Depreciation & Amortization | -- | -18.25% | -10.57% | -13.18% | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -2.97% | -47.11% | 7.99% | -16.93% | -60.73% |
| Operating Income | 2.97% | 65.33% | -19.89% | 7.39% | -14.79% |
| Income Before Tax | -413.27% | -3,014.33% | 51.19% | 74.01% | 127.64% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -413.27% | -3,014.33% | 51.19% | 74.01% | 127.64% |
| Earnings from Discontinued Operations | 58.34% | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.50% | -3,014.33% | 51.19% | 74.01% | -56.14% |
| EBIT | 2.97% | 65.33% | -19.89% | 7.39% | -14.79% |
| EBITDA | 4.41% | 74.24% | -42.27% | 4.46% | -62.72% |
| EPS Basic | 77.78% | 33.91% | 81.28% | 69.22% | -154.45% |
| Normalized Basic EPS | -151.31% | -566.32% | 89.47% | 92.55% | 112.14% |
| EPS Diluted | 77.78% | 33.91% | 81.28% | 69.22% | -154.47% |
| Normalized Diluted EPS | -151.31% | -566.32% | 89.47% | 92.55% | 112.14% |
| Average Basic Shares Outstanding | 510.51% | 325.13% | 363.68% | 248.88% | 127.90% |
| Average Diluted Shares Outstanding | 510.51% | 325.13% | 363.68% | 248.88% | 127.90% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |